Konstantinos Xynos Sells 11,447 Shares of Replimune Group (NASDAQ:REPL) Stock

Posted by George Bondi on Aug 14th, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This represents a 4.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

Shares of REPL stock opened at $15.19 on Friday. The company has a market cap of $1.28 billion, a P/E ratio of -4.49 and a beta of 0.88. The business has a 50 day moving average of $10.55 and a two-hundred day moving average of $7.74. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $15.71. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL – Get Free Report) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, analysts anticipate that Replimune Group, Inc. will post -2.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Finally, Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Moderate Buy” and a consensus price target of $11.86.

Get Our Latest Stock Report on Replimune Group

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

Positive Sentiment: $150 million financing improves liquidity: Replimune priced a $150 million underwritten offering, providing additional capital to fund development of RP1 and its broader oncology pipeline. The financing reduces near-term funding concerns, although it will dilute existing shareholders. Replimune Announces Pricing of $150 Million Underwritten Offering
Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target to $20, while other firms upgraded or increased their targets, helping support investor sentiment. The broader analyst consensus remains below the recent trading range, however. Replimune Shares Rise After Pricing of Offering
Neutral Sentiment: Insiders sold shares for tax withholding: The CEO, CFO, chief accounting officer and another insider collectively sold about 69,868 shares worth approximately $906,000. The filings said the transactions were used to cover taxes on vested equity awards, and the executives retained substantial holdings, limiting the negative signal. SEC insider transaction filing
Negative Sentiment: Multiple law firms publicized a securities class action: The lawsuit alleges that Replimune misled investors about RP1’s efficacy, commercial readiness and unresolved FDA concerns. The allegations relate to securities purchased from October 20, 2025, through April 10, 2026, when shares fell after the FDA rejected the company’s application and said previously communicated study-design concerns had not been addressed. The lead-plaintiff deadline is October 5, 2026. The claims have not been proven, but the litigation creates legal, financial and reputational uncertainty. Replimune securities lawsuit notice

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in REPL. BlackRock Inc. bought a new position in shares of Replimune Group in the second quarter worth $99,171,000. RTW Investments LP raised its stake in shares of Replimune Group by 11.6% during the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after purchasing an additional 744,620 shares in the last quarter. State Street Corp lifted its holdings in Replimune Group by 26.3% in the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. lifted its holdings in Replimune Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares during the period. Finally, Balyasny Asset Management L.P. grew its position in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.